The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Breast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases
Open accessAbstract
BACKGROUND: The importance of cross-talk between a cancer and its microenvironment has been increasingly recognized. We hypothesized that mutational inactivation of the tumor-suppressor gene TP53 and genomic alterations in stromal cells of a tumor's microenvironment contribute to the clinical outcome. METHODS: We performed TP53 mutation analysis and genomewide analysis of loss of heterozygosity and allelic imbalance on DNA from isolated neoplastic epithelial and stromal cells from 43 patients with hereditary breast cancer and 175 patients with sporadic breast cancer. Compartment-specific patterns and TP53 mutations were analyzed. Associations between compartment-specific TP53 status, loss of heterozygosity or allelic imbalance, and clinical and pathological characteristics were computed. RESULTS: TP53 mutations were associated with an increased loss of heterozygosity and allelic imbalance in both hereditary and sporadic breast cancers, but samples from patients with hereditary disease had more frequent mutations than did those from patients with sporadic tumors (74.4% vs. 42.3%, P=0.001). Only 1 microsatellite locus (2p25.1) in stromal cells from hereditary breast cancers was associated with mutated TP53, whereas there were 66 such loci in cells from sporadic breast cancers. Somatic TP53 mutations in stroma, but not epithelium, of sporadic breast cancers were associated with regional nodal metastases (P=0.003). A specific set of five loci linked to an increased loss of heterozygosity and allelic imbalance in the stroma of sporadic tumors was associated with nodal metastases in the absence of TP53 mutations. No associations were found between any of the clinical or pathological features of hereditary breast cancer with somatic TP53 mutations. CONCLUSIONS: Stroma-specific loss of heterozygosity or allelic imbalance is associated with somatic TP53 mutations and regional lymph-node metastases in sporadic breast cancer but not in hereditary breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Wacholder, S., Chanock, S., Garcia-Closas, M., El ghormli, L., & Rothman, N. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh075 · Cited by 1,754
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes
Antoniou, A. C., Pharoah, P. D. P., McMullan, G., Day, N. E., Stratton, M. R., Peto, J., Ponder, B. J., & Easton, D. F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600008 · Cited by 495
The Influence of Extracellular Matrix on Gene Expression: Is Structure The Message?
Bissell, M. J., & Barcellos-Hoff, M. H. (1987) · Journal of Cell Science · doi:10.1242/jcs.1987.supplement_8.18 · Cited by 435
Kurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418
Self-citationMalignant transformation in a nontumorigenic human prostatic epithelial cell line.
Hayward, S. W., Wang, Y. Z., Cao, M., Hom, Y. K., Zhang, B., Grossfeld, G. D., Sudilovsky, D., & Cunha, G. R. (2001) · PubMed · Cited by 345
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…considered to be equivalent, evidence is accumulating to indicate that different mutants show a distinct profile with respect to loss of wild-type p53 activity, the ability to inhibit wild-type p53, and the acquisition of gain of function (Table 1; Halevy et al., 1990; Petitjean et al., 2007).”
BackgroundDiversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Stromal biology and therapy in pancreatic cancer
Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., et al. (2011) · Gut · doi:10.1136/gut.2010.226092 · Cited by 757
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Gene expression profiling of the tumor microenvironment during breast cancer progression
Ma, X.-J., Dahiya, S., Richardson, E., Erlander, M., & Sgroi, D. C. (2009) · Breast Cancer Research · doi:10.1186/bcr2222 · Cited by 629
Co-evolution of tumor cells and their microenvironment
Polyak, K., Haviv, I., & Campbell, I. G. (2009) · Trends in Genetics · doi:10.1016/j.tig.2008.10.012 · Cited by 628
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57099 · Cited by 616
Giannoni, E., Bianchini, F., Masieri, L., Serni, S., Torre, E., Calorini, L., & Chiarugi, P. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0785 · Cited by 596
Cancer-associated fibroblasts and tumor growth – bystanders turning into key players
Östman, A., & Augsten, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.003 · Cited by 543
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
Cirri, P., & Chiarugi, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9340-x · Cited by 519
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
“Expression ofmutated p53 has been demonstrated in sporadic breast cancer CAFs [91] and”
BackgroundFibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 474
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448
Martinez-Outschoorn, U. E., Lisanti, M. P., & Sotgia, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.005 · Cited by 423
Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
Kakarala, M., & Wicha, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3931 · Cited by 403
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
‘Cancer associated fibroblasts’ – more than meets the eye
Madar, S., Goldstein, I., & Rotter, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.004 · Cited by 362
Soto, A. M., & Sonnenschein, C. (2011) · BioEssays · doi:10.1002/bies.201100025 · Cited by 349
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Mesenchymal stem cells: the fibroblasts' new clothes?
Haniffa, M. A., Collin, M. P., Buckley, C. D., & Dazzi, F. (2009) · Haematologica · doi:10.3324/haematol.13699 · Cited by 345
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression
Shimoda, M., Mellody, K. T., & Orimo, A. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.002 · Cited by 325
Witkiewicz, A. K., Dasgupta, A., Sotgia, F., Mercier, I., Pestell, R. G., Sabel, M., Kleer, C. G., Brody, J. R., & Lisanti, M. P. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080873 · Cited by 283
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., Snyder, E., Faversani, A., Coggi, G., Flavin, R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907676107 · Cited by 267
Paulsson, J., Sjöblom, T., Micke, P., Pontén, F., Landberg, G., Heldin, C.-H., Bergh, J., Brennan, D. J., Jirström, K., & Östman, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081030 · Cited by 266
Kharaishvili, G., Simkova, D., Bouchalova, K., Gachechiladze, M., Narsia, N., & Bouchal, J. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-41 · Cited by 197
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
A Multimodal Knowledge-enhanced Whole-slide Pathology Foundation Model
Xu, Y., Wang, Y., Zhou, F., Ma, J., Jin, C., Yang, S., Li, J., Zhang, Z., Zhao, C., Zhou, H., et al. (2024) · arXiv · doi:10.48550/arxiv.2407.15362 · Cited by 60
Self-citation
Metadata
- Authors
- Patocs, A., Zhang, L., Xu, Y., Weber, F., Caldes, T., Mutter, G. L., Platzer, P., & Eng, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-20
- Volume
- 357
- Issue
- 25
- Pages
- 2543-2551
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058693971
- Cited by
- 297
- References
- 38
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.